Total Valuation
Instadose Pharma has a market cap or net worth of $532.00. The enterprise value is $53.19K.
Market Cap$532.00
Enterprise Value$53.19K
Share Statistics
Instadose Pharma has 531,933,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding531,933,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Instadose Pharma’s return on equity (ROE) is 4.64 and return on invested capital (ROIC) is 372.55%.
Return on Equity (ROE)4.64
Return on Assets (ROA)-196.33
Return on Invested Capital (ROIC)372.55%
Return on Capital Employed (ROCE)3.73
Revenue Per Employee0.00
Profits Per Employee-180.80K
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Instadose Pharma is ―. Instadose Pharma’s PEG ratio is -2.09.
PE Ratio―
PS Ratio0.00
PB Ratio-14.53K
Price to Fair Value-14.53K
Price to FCF-22.29M
Price to Operating Cash Flow-90.55
PEG Ratio-2.09
Income Statement
In the last 12 months, Instadose Pharma had revenue of 0.00 and earned -589.00K in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit0.00
Operating Income-462.02K
Pretax Income-462.02K
Net Income-589.00K
EBITDA-100.43K
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was 160.40K and capital expenditures 0.00, giving a free cash flow of 160.40K billion.
Operating Cash Flow160.40K
Free Cash Flow160.40K
Free Cash Flow per Share<0.01
Dividends & Yields
Instadose Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-56.00
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)―
Important Dates
Instadose Pharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Instadose Pharma as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Instadose Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Instadose Pharma EV to EBITDA ratio is -18.38K, with an EV/FCF ratio of -22.29M.
EV to Sales0.00
EV to EBITDA-18.38K
EV to Free Cash Flow-22.29M
EV to Operating Cash Flow-22.29M
Balance Sheet
Instadose Pharma has $5.33K in cash and marketable securities with $237.52K in debt, giving a net cash position of -$232.20K billion.
Cash & Marketable Securities$5.33K
Total Debt$237.52K
Net Cash-$232.20K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Instadose Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―